⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101638 | 0.67 | — | — | |
| SCHEMBL5838655 | 0.64 | — | — | |
| SCHEMBL22206279 | 0.64 | — | — | |
| Ammonia Solution, Strong SCHEMBL238233 | 0.64 | — | — | |
| SCHEMBL6054151 | 0.64 | — | — | |
| Ammonia Solution, Strong SCHEMBL6268326 | 0.62 | — | — | |
| SCHEMBL1592588 | 0.58 | — | — | |
| SCHEMBL3195434 | 0.58 | — | — | |
| SCHEMBL8743605 | 0.58 | — | — | |
| SCHEMBL445070 | 0.57 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902401-B | Receptor inhibitors, pharmaceutical compositions comprising the same and uses thereof | 北京泰德制药股份有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | claimed |
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | claimed |
| US-3957984-A | ANTIBACTERIAL, ANTIBIOTICS | SMITHKLINE CORPORATION (US) | 1976-05-18 | — | — | US | claimed |
| JP-51125398-A | — | — | None | — | — | JP | disclosed |
| EP-3523291-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018065768-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
| US-20170156315-A1 | METHODS AND COMPOSITIONS OF GRANULE FORMULATIONS | AGROFRESH, INC. | 2017-06-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2011010083-A1 | INDOLYL-PYRIDONE DERIVATIVES | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | WO | disclosed |
| US-6344209-B1 | BIODEGRADABLE POLYLACTIC ACID, POLYGLYCOLIC ACID AND COPOLYMERS OF THE TWO FOR BONE DISEASES THERAPY; ANTIBIOTICS, ANTI-INFLAMMATORY AND ANTI-TUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| JP-S51125398-A | A PROCESS FOR PREPARING 7-SUBSTITUTED ALKANAMIDE-3-SUBSTITUTED THIOMET HYL-3-CEPHEM-4-CARBOXYLIC ACIDS | FUJISAWA PHARMACEUT CO LTD | 1976-11-01 | — | — | JP | disclosed |